Evidence map›Paper›PMID 27141270›Full record

ArticleIranian journal of neurology2016

Headache in relapse and remission phases of multiple sclerosis: A case-control study.

Mansoureh Togha, Nahid Abbasi Khoshsirat, Abdorreza Naser Moghadasi, Faezeh Mousavinia, Mohammad Mozafari, Mohamadreza Neishaboury, Seyed Mahmood Mousavi

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Headache in Multiple Sclerosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mansoureh ToghaHeadache Research Center, Iranian Center of Neurological Research, Neuroscience Institute AND Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Nahid Abbasi KhoshsiratHeadache Research Center, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abdorreza Naser MoghadasiHeadache Research Center, Iranian Center of Neurological Research, Neuroscience Institute AND Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Faezeh MousaviniaDepartment of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad MozafariHeadache Research Center, Iranian Center of Neurological Research, Neuroscience Institute AND Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mohamadreza NeishabouryHeadache Research Center, Iranian Center of Neurological Research, Neuroscience Institute AND Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Mahmood MousaviHeadache Research Center, Iranian Center of Neurological Research, Neuroscience Institute AND Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHeadaches are one of the most frequent reasons for pain in multiple sclerosis (MS) individuals. Characterization of headaches and delineating possible relationships with MS-related determinants can ultimately circumvent headaches.

methodsIn a prospective case-control study, 65 Iranian relapsing-remitting MS (RRMS) patients and 65 healthy controls were recruited during patients' admission for attack-period treatment and asked about characteristics and co-symptoms of headaches they experienced in the preceding week and usage of disease modifying drugs (DMDs) and types of MS attacks were also inquired. The same questions were asked from the same patients 3 months later in a follow-up visit.

resultsA total of 57 patients and 57 controls were included in the final analyses. In total, 26 (45.6%) patients in relapse, 18 (27.7%) controls, and 22 (38.6%) patients in remission reported headaches and only significant difference existed between relapse patients and controls (P = 0.036). In headache prevalence was higher in patients in relapse phase having MS < 3 years compared to relapse patients with more than 3 years of MS (68 vs. 28.1%; P = 0.004). Other variables of interest did not differ among the three groups.

conclusionThe RRMS patients in relapse phase suffer from headaches more than healthy people do.

Indexed as

Case-Control StudiesHeadacheMultiple SclerosisRelapseRemission

Identifiers

PMID27141270
PMCPMC4852065
OpenAlexW2232512310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.